ClinicalTrials.Veeva

Menu

A Clinical Evaluation of the Treatment of Spider Veins on the Ankles

Cutera logo

Cutera

Status

Completed

Conditions

Spider Veins

Treatments

Device: Nd:YAG laser

Study type

Interventional

Funder types

Industry

Identifiers

NCT02754479
C-16-EV07

Details and patient eligibility

About

To evaluate the safety and effectiveness of the Excel V system for the treatment of lower extremity spider veins on the ankles.

Full description

The purpose of this study is to evaluate the real-world effectiveness of the 532 nm and 1064 nm Nd:YAG lasers within the Cutera Excel V system for the treatment of lower extremity spider veins, specifically on the ankles, within a clinic setting.

Enrollment

4 patients

Sex

All

Ages

20 to 75 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  1. Males or females, 20 to 75 years of age (inclusive).
  2. Fitzpatrick Skin Type I - III.
  3. Having spider veins on at least 1 ankle measuring 2.0mm or less in diameter, linear or branching, and red, pink, blue and/or purple in color, as assessed by the investigator.
  4. Having spider veins on the ankle that are appropriate for laser treatment, as assessed by the investigator.
  5. Subject must be able to read, understand and sign the Informed Consent Form.
  6. Subject must be willing and able to adhere to the treatment and follow-up schedule and post-treatment care instructions.
  7. Wiling to have limited sun exposure for the duration of the study, including the follow-up period.
  8. Willingness to have digital photographs taken of ankle spider veins and agree to use of photographs for presentation, educational or marketing purposes.
  9. Agree not to undergo any other procedure for the treatment of ankle spider veins during the study.

Exclusion criteria

  1. Fitzpatrick Skin Type IV - VI.
  2. Pregnant.
  3. Having an infection, dermatitis or a rash in the treatment area.
  4. Having significant varicosities or perforator veins.
  5. History of pigmentary disorders, particularly tendency for hyper- or hypo-pigmentation.
  6. Systemic use of isotretinoin (Accutane®) within 6 months of study participation.
  7. Excessively tanned in areas to be treated or unable/unlikely to refrain from tanning during the study.
  8. In the opinion of the investigator, any physical or mental condition which might make it unsafe for the subject to participate in this study or which requires systemic therapy that could interfere with this research study.

Trial design

Primary purpose

Treatment

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

4 participants in 1 patient group

Laser treatments
Experimental group
Description:
Each subject will receive a combination of 532 nm and/or 1064 nm Nd:YAG laser treatment
Treatment:
Device: Nd:YAG laser

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems